Laura Gault
Chief Tech/Sci/R&D Officer bij SAGE THERAPEUTICS, INC.
Vermogen: 215 079 $ op 31-03-2024
Profiel
Laura Gault is currently the Chief Medical Officer at SAGE Therapeutics, Inc. Prior to her current position, she worked as the Vice President at Alexion Pharmaceuticals, Inc. from 2019 to 2022 and as the Vice President-Neurology Clinic Development at Vertex Pharmaceuticals, Inc. from 2017 to 2019.
Gault received her undergraduate degree from the University of Pittsburgh and her doctorate from Case Western Reserve University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
SAGE THERAPEUTICS, INC.
0.02% | 13-02-2024 | 11 477 ( 0.02% ) | 215 079 $ | 31-03-2024 |
Actieve functies van Laura Gault
| Bedrijven | Functie | Begin |
|---|---|---|
| SAGE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31-10-2022 |
Eerdere bekende functies van Laura Gault
| Bedrijven | Functie | Einde |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-11-2022 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01-03-2019 |
Opleiding van Laura Gault
| University of Pittsburgh | Undergraduate Degree |
| Case Western Reserve University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| SAGE THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
